M
yocarditis is an inflammatory myocardial process with variable presentation and clinical course in children. Although the classic presentation is that of new-onset heart failure after a viral prodrome, other presentations include chest pain, arrhythmia, sudden death, or a fulminant disease with severe heart failure. 1 In a recent analysis of 514 children who were hospitalized in the United States (US) with myocarditis, 23% were supported with either extracorporeal membrane oxygenation or a ventricular assist device during the acute disease. 2 Although a majority of children with myocarditis recover, some have severe and persistent heart failure resulting in death or heart transplantation (HT).
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See Clinical Perspective
Thus, although recovery is the most desirable outcome in children with myocarditis, 3 HT may be lifesaving in some with persistent, severe heart failure. Whether post-transplant survival in such children is similar to those transplanted for idiopathic dilated cardiomyopathy (IDC) has been recently questioned. 4 In an analysis of merged data from the Pediatric Cardiomyopathy Registry (PCMR) and the Pediatric Heart Transplant Study (PHTS), Pietra et al reported shorter posttransplant survival in children with myocarditis compared with children with IDC and described an independent association of myocarditis with post-transplant mortality. 4 They suggested that this may be because of viral or inflammatory factors associated with myocarditis which may adversely impact graft survival. 4 If true, a child who has persistent heart failure because of myocarditis-and for whom recovery is deemed unlikely-would also benefit less from HT compared with a child with IDC with equally severe heart failure. Outcomes in Children With Myocarditis survival is because of higher baseline risk related to heart failure severity. It is notable that previous studies have not described a difference in risk of wait-list mortality (unadjusted or adjusted) between these groups. We hypothesized that among children listed for HT, those with myocarditis are sicker at listing and at HT compared with children with IDC and are at higher risk of wait-list and post-transplant mortality. However, these differences in outcomes are because of the differences in heart failure severity at the time of listing/transplant, and myocarditis is not an independent risk factor for mortality.
Methods
Study Population
We identified all children <18 years of age between July 1, 2004, and December 31, 2013, who were listed for HT in the US with a diagnosis of myocarditis or IDC in the Organ Procurement and Transplant Network (OPTN) database. The OPTN database includes demographic and clinical information at listing in all wait-listed candidates and at transplant in all HT recipients in the US submitted by their transplant centers and provided to investigators as deidentified data. Such analyses are waived for review by our institutional review board. The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the OPTN contractor, United Network of Organ Sharing. We excluded children with a primary diagnosis of structural heart disease and those listed for heart retransplantation or multiorgan transplantation.
Study Design and Definitions
We compared baseline characteristics and outcomes in children with myocarditis and those with IDC listed for HT during the study period. The primary end point for wait-list outcomes was a composite of death on the wait-list or becoming too sick to transplant (removal from the list because of clinical deterioration). The primary end point for posttransplant outcomes was a composite of death or graft loss (retransplantation). For analysis of wait-list outcomes, children were followed from the time of listing until death, HT, removal from the list, or the day of last observation as on March 1, 2014. Children removed from the list because of reasons other than deterioration were censored. For analysis of post-transplant outcomes, children who received HT were followed until death, retransplantation, or the day of last observation.
Baseline variables were examined both at listing and at transplant and were defined at listing for analysis of wait-list outcomes and at transplant for analysis of post-transplant outcomes. Race/ethnicity was analyzed as white, black, Hispanic, or other. Renal function was analyzed as estimated glomerular filtration rate (GFR; mL/min per 1.73 m 2 ) and calculated from serum creatinine using the modified Schwartz formula. 6 For children ≥1 year of age, normal renal function was defined as GFR >60, moderate dysfunction as GFR 30 to 60, and severe dysfunction as GFR <30 or dialysis support. 7 For infants <1 year of age, normal renal function was defined as GFR >40, moderate dysfunction as GFR 20 to 40, and severe dysfunction as GFR <20 or dialysis support. 7 None of the study children had missing data for the variables age, sex, race/ethnicity, blood type, assisted ventilation and mechanical circulatory support at listing or at transplant, medical insurance (Medicaid), United Network of Organ Sharing listing status, dialysis and the dates of listing, transplant, death, or removal from the wait-list. For children with missing values of serum creatinine at listing (2.1%) and at transplant (2.9%), we used a multiple imputation technique to impute their GFR using clinical variables at listing and at transplant, respectively; 10 imputations were used for each missing value. 8 
Statistical Analysis
Baseline data are presented as median (25th, 75th percentile) or number (percent). Baseline characteristics in children with myocarditis and IDC were compared using the Fisher exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Wait-list outcomes in children with myocarditis and IDC were characterized using competing outcomes analysis. 9, 10 A multivariable Cox proportional hazards model for the composite wait-list end point was developed using a forward selection procedure, retaining variables significant at the 0.10 level based on a likelihood ratio test; all variables listed in Table 1 except those with large missing data (mean pulmonary artery pressure, pulmonary capillary wedge pressure) were considered. Post-transplant survival (freedom from death or retransplantation) was characterized using Kaplan-Meier analysis and compared between groups using the log-rank test. A Cox model was developed to compare the risk of post-transplant mortality (or graft loss) between the 2 groups adjusted for baseline risk factors. Assumptions for Cox models were evaluated for both wait-list and post-transplant end points. Data were analyzed using SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC). All statistical tests were 2-sided, and a P value <0.05 was used to define statistical significance.
Results
Study Population
During the study period, 4552 children <18 years of age were listed in the US for primary HT. Of these, 1804 had myocarditis or IDC as their listing diagnosis and formed the study cohort. Of these, 221 (12%) had myocarditis and 1583 (88%) had IDC. Baseline characteristics of listed children in these groups are compared in Table 1 .
Children with myocarditis were more likely to be listed with the highest urgency (status 1A) compared with children with IDC (86% versus 75%; P<0.001). They were also more likely to be supported using assisted ventilation (49% versus 23%; P<0.001) on mechanical circulatory support (45% versus 19%; P<0.001) and have renal dysfunction (47% versus 38%; P=0.004) at listing.
Wait-List Outcomes
Overall, 179 (4%) children reached the wait-list end point (121 died and 58 became too sick to transplant). Thirty-nine (18%) children with myocarditis (27 deaths and 12 delisted for deterioration) and 140 (9%) with IDC (94 deaths and 46 delisted for deterioration) reached the wait-list end point. In unadjusted analysis, children with myocarditis were more likely to die waiting or become too sick to transplant (hazard ratio In multivariable analysis, independent risk factors for waitlist mortality (or becoming too sick to transplant) were age <1 year, assisted ventilation, mechanical circulatory support, and renal dysfunction (Table 2) . Adjusted for these factors, myocarditis was not associated with wait-list mortality (HR 1.3, 95% CI 0.9, 1.9; P=0.11). A higher proportion of children with myocarditis were removed from the list because of recovery compared with those with IDC (17% versus 7%).
Post-Transplant Outcomes
Overall, 137 children with myocarditis and 1249 children with DCM received HT. Table 3 compares baseline characteristics at the time of HT between the 2 groups. Children with myocarditis were more likely to be supported using assisted ventilation (27% versus 17%; P=0.006) or on mechanical circulatory support (53% versus 30%; P<0.001) at HT compared with children with IDC. The median wait time for HT was 30 days (interquartile range 10, 76 days) in children with myocarditis and 36 days (interquartile range 13, 83 days) in children with IDC (P=0. 19 ).
The median post-transplant follow-up was 3.1years (interquartile range 1.0, 5.1 years). Of children with myocarditis, 27 (20%) children died or were retransplanted (22 deaths and 5 retransplants), whereas 183 children (15%) with IDC died or were retransplanted (148 deaths and 35 retransplants). Figure 3 illustrates post-transplant Kaplan-Meier survival in the 2 groups. In unadjusted analysis, there was a trend toward higher risk of post-transplant mortality in children with myocarditis (HR 1.4; 95% CI 1.0-2.2; P=0.05). The higher risk of mortality in children with myocarditis appeared to be limited to the first few weeks after transplant, and survival curves were parallel after the early post-transplant period ( Figure I in the Data Supplement). In children transplanted while supported on a ventricular assist device, post-transplant survival was similar in children with myocarditis and IDC (P=0.17; Figure II in the Data Supplement). In multivariable analysis, independent risk factors for post-transplant mortality (or graft loss) were age <1 year, female sex, black race, mechanical circulatory support at the time of HT, and renal dysfunction (Table 4) . In an analysis adjusted for these factors, myocarditis was not associated with risk of graft loss (HR 1.3, 95% CI 0.9, 2.0; P=0.22). The proportion of transplanted children treated for acute rejection during the first post-transplant year was similar (12.4% of myocarditis versus 10.9% of IDC patients; P=0.57) as was the proportion of patients with graft loss after acute rejection (P=0.24).
Discussion
In this study, we compared baseline characteristics and outcomes in children with myocarditis and IDC listed for HT in the US during a recent 10-year period. We found that children with myocarditis were more likely to be supported using assisted ventilation or mechanical circulatory support and have renal dysfunction compared with children with IDC-both at listing and at transplant. In unadjusted analysis, children with myocarditis were at a higher risk of wait-list and post-transplant mortality compared with children with IDC; the higher risk of post-transplant mortality appeared limited to the first few weeks post-transplant. After adjusting for baseline risk factors, however, myocarditis did not confer additional risk for wait-list or post-transplant mortality. These findings suggest that heart failure severity at the time of listing and HT is able to explain the higher risk of wait-list and post-transplant mortality, respectively, in children with myocarditis, and the diagnosis of myocarditis is not an independent risk factor for these outcomes.
Kirk et al analyzed 1098 children listed for HT with a diagnosis of dilated cardiomyopathy and enrolled in the PHTS during 1993-2006. 11 Of these, 133 (12%) had myocarditis. Overall, 861 of 1098 children received HT. Diagnostic subgroups of dilated cardiomyopathy (such as myocarditis) were not at higher risk of post-transplant mortality in multivariable analysis. 11 Recipient factors associated with post-transplant mortality were assisted ventilation at transplant for earlyphase mortality and older age at transplant and black race for late-phase mortality. In a subsequent PHTS report, 4 Pietra et al limited their analysis to 261 children with dilated cardiomyopathy enrolled in the PHTS during 1993 to 2005 who were previously followed in the PCMR since diagnosis (29 of 261 had myocarditis). Of 209 children who received HT (23 with myocarditis), those with myocarditis had shorter posttransplant survival compared with the remaining children with dilated cardiomyopathy (65% versus 85% 3-year survival). In a multivariable model, the risk of post-transplant mortality associated with myocarditis was significant (HR 2.7, 95% CI 1.3, 5.8). The discrepant results of these studies-in particular, the risk of post-transplant mortality associated with myocarditis-are difficult to explain. The latter cohort was a subgroup of the former cohort, myocardial biopsy was not required to diagnose myocarditis in either study, the percentage of children with myocarditis were similar in these analyses, and the analysis showing lack of association (Kirk et al) had a much larger sample size, making it unlikely that their failure to detect the association was as a result of a type 2 error. 4, 11 It is important to consider how the diagnosis of myocarditis was made when interpreting outcome analyses in myocarditis cohorts. Myocarditis has been defined in PCMR as a presentation of new-onset cardiac symptoms and echocardiographic abnormalities developing after a history of recent respiratory, gastrointestinal, or other suspected viral infection. 3 Notably, only 32% of children with myocarditis in PCMR have biopsy confirmation; the remaining children have been defined as having probable myocarditis based on the clinical definition above. 3 The outcomes (death, transplantation, recovery over 3 years) in children with probable myocarditis have been shown to be similar to those with biopsy-confirmed myocarditis. 3 Although the OPTN database-the source of data for the current analysis-does not have information regarding how the diagnosis of myocarditis was made, it is likely that the clinicians reporting this diagnosis in the OPTN database used a definition similar to the PCMR definition above. It is not surprising then that the proportion of children with myocarditis in the current cohort (12% of subjects) is similar to the proportion of children with myocarditis in the PHTS and the PCMR-PHTS analyses described above. In this context, the joint statement by the American Heart Association, the American College of Cardiology, and the European Society of Cardiology recommending myocardial biopsy to diagnose myocarditis only under specific conditions and not in all subjects is of particular relevance. 12 The risk factors associated with post-transplant mortality in the current analysis are not new and are similar to those reported previously. [13] [14] [15] [16] Indeed, several investigators have suggested using a combination of baseline risk factors-either using a score-based tool or a more sophisticated statistical model-to risk-stratify pediatric HT recipients for early posttransplant mortality. 5, 15, 17, 18 The specific risk factors in these models may vary somewhat but, considered broadly, include younger age or congenital heart disease (markers of surgical complexity), level of hemodynamic support at transplant (a marker of heart failure severity), and presence of end-organ [18] [19] [20] A common analytic approach in clinical epidemiology when evaluating new risk factors (such as myocarditis) is to adjust for known risk factors even when they are not statistically significant in the cohort analyzed so that their confounding effect is accounted for. Our results suggest that the association of myocarditis with post-transplant survival is confounded by heart failure severity at the time of HT. This is further supported by our analysis of wait-list mortality which was associated with myocarditis in unadjusted analysis but not when baseline risk factors of heart failure severity were included in the model.
Our findings have important clinical implications. Ventricular function recovers completely in many children with severe myocarditis, and therefore, a clinician's hesitation in listing even the sickest children with myocarditis early in their course is prudent because of their potential for recovery. 21, 22 For children in whom ventricular function does not recover, myocarditis is potentially lethal, and therefore, evaluation for HT is reasonable in those with persistence of severe heart failure. 2 The process of HT evaluation encompasses a careful assessment of risk factors and estimating the risk of wait-list and post-transplant mortality in all candidates. 5 Our results do not support the notion of additional risk attributable to the diagnosis of myocarditis over and above that inherent in the severity of heart failure. Because our analysis is limited to children who were already listed for HT and it is unknown whether specific clinical, viral, and immunologic factors (such as duration between presentation and listing, specific viral agent identified, or active viremia) were considered before listing, how these factors contribute to post-transplant risk remains unknown.
This study has limitations. First, this was a retrospective analysis of the OPTN database. Retrospective studies are vulnerable to selection bias if the cohort is not representative of the study population. This is unlikely to be important for the current analysis because submission of patient data is mandatory at listing and HT, and all patients are included. Second, the quality of registry data is inherently less robust than data collected for prospective studies. However, the OPTN data are used for real-time heart allocation, are subject to periodic audit, and are used for generating center-performance reports, ensuring certain safeguards to their quality. Third, we do not know whether the diagnosis of myocarditis in study subjects was made clinically, by imaging, or by myocardial biopsy, as discussed earlier.
In conclusion, among children listed for HT, those with a diagnosis of myocarditis are at higher risk for wait-list and post-transplant mortality compared with children with IDC. However, these differences in outcomes may be explained by the differences in severity of illness between the groups at the time of listing and transplant, respectively, and myocarditis is not an independent risk factor for mortality. 
